The University of Cape Town’s (UCT) Holistic Drug Discovery and Development Centre (H3D) has proudly launched the Centre for Translational AMR Research (CTAR) Programme, backed by a substantial £5 million investment from LifeArc. This strategic partnership aims to combat the escalating threat of antimicrobial resistance (AMR), particularly focusing on multidrug-resistant (MDR) gram-negative bacteria such as Acinetobacter baumannii.

Both Professor Kelly Chibale, the director of H3D; and Dr Dave Powell, the chief scientific officer at LifeArc, delivered opening addresses for the launch on 3 December, highlighting the innovative approaches being taken to tackle AMR. They also emphasised the importance of strengthening local research capacity in Africa through knowledge exchange and collaborative efforts.

Read more.